The developing landscape of diabetes care is experiencing a remarkable shift, driven by new incretin-based therapies. Currently, semaglutide has achieved considerable attention, but emerging medications like tirzepatide, retatrutide, and cagrilintide are ready to alter the outlook. Tirzepatide, a